Clinical Trial Update: Clinical Study to Evaluate the Tolerability, Safety and Efficacy of Enteric-coated Mycophenolate Sodium, After Equimolar Conversion From Mycophenolate Mofetil (MMF), in Patients With Stable Renal Transplant Receiving Tacrolimus [Phase 3]

View source ↗

Summary

A Phase 3 study completed evaluating tolerability, safety, and efficacy of enteric-coated mycophenolate sodium after equimolar conversion from mycophenolate mof…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kidney Transplantation
• Rejection of Transplanted Kidney

Drugs mentioned

• CELLCEPT (mycophenolate mofetil hydrochloride)
• MYFORTIC (MYCOPHENOLIC ACID)

Snippet

Sponsor: Novartis | Conditions: Prevention of Acute Rejection After Kidney Transplantation | Phase 3 | Status: COMPLETED